This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Depression and Anxiety in Oncology: The Psychiatrist’s Perspective

Ray M. F. Berard, M.D.

Published: July 1, 2001

Article Abstract
‘ ‹’ ‹

Depression and anxiety are frequently undiagnosed and untreated in cancer patients, resulting in a significant negative impact on quality of life and disease outcome. Furthermore, although effective therapies for depression and anxiety are available, there have been few clinical trials of pharmacotherapy in cancer patients. This article explores how the diagnosis of depression and anxiety can be improved in cancer patients and reviews current treatment options in the oncology setting. The Hospital Anxiety and Depression Scale, a simple, patient-administered questionnaire, is effective in screening for psychiatric symptoms at an early stage of cancer treatment, particularly if vulnerable individuals can be identified and targeted. Selective serotonin reuptake inhibitors are currently first-choice therapy for depression, and many of the drugs in the class are effective in anxiety disorders. Further studies of these agents in the oncology setting are warranted.’ ‹’ ‹’ ‹’ ‹’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 62

Quick Links: Depression (MDD)


Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...